My watch list
my.bionity.com  
Login  

Alligator Bioscience to Receive USD 6 Million Milestone Payment from Janssen

08-Jan-2018

Alligator Bioscience announced that a development milestone payment of USD 6 million has been triggered under the partnership agreement for ADC-1013 (JNJ-64457107) with Janssen Biotech, Inc.

The milestone payment is for the partnership agreement to initiate a clinical combination study of ADC-1013 with one of Janssen's proprietary PD-1 inhibitors. This is the first out of a number of pre-defined milestones, related to the start of combination or phase II studies as part of the ADC-1013 clinical program, which all together have an aggregated potential value of 35 MUSD.

The licensing agreement with Janssen Biotech Inc. encompasses milestone payments up to a potential total value of USD 695 million.  Alligator is also eligible to receive tiered royalties on worldwide net sales upon successful launch and commercialization of ADC-1013.

"We are pleased that our collaboration with Janssen is continuing to progress according to plan", said Per Norlén, CEO at Alligator Bioscience. "The upcoming combination is a very important step in the continued clinical development. Synergy between ADC-1013 and PD-1 blocking antibodies is supported by pre-clinical data. If this translates to the clinic, it could create new treatment opportunities for many cancer patients".

Alligator's partner Janssen Biotech, Inc. is performing a phase I dose-escalation clinical study (ClinicalTrials: NCT02829099) with intravenous administration of JNJ-64457107 (ADC-1013). This study is ongoing with approximately 50 patients recruited to date.

Facts, background information, dossiers
  • Janssen Biotech
  • Alligator Bioscience
  • milestone payments
More about Alligator Bioscience
More about Janssen
  • News

    MorphoSys Sues Janssen Biotech and Genmab for Patent Infringement

    MorphoSys AG announced that it filed a lawsuit in the United States (U.S.) District Court of Delaware against Janssen Biotech, and Genmab, A/S for patent infringement of U.S. Patent Number 8,263,746. This patent, which is owned by MorphoSys, describes and claims antibodies with particular f ... more

    Genmab achieves USD 45 million milestone

    Genmab A/S announced it has achieved a USD 45 million milestone in its DARZALEX™ (daratumumab) collaboration with Janssen Biotech, Inc. The milestone payment was triggered by the first commercial sale of DARZALEX in the United States. "Today marks a significant moment in the history of Genm ... more

    Genmab Announces Phase II Study of Daratumumab in Non-Hodgkin’s Lymphomas

    Genmab A/S announced that its collaboration partner, Janssen Biotech, Inc. (Janssen) plans to start a Phase II study of daratumumab in non-Hodgkin’s lymphomas (NHL).  The study (LYM2001) will evaluate daratumumab monotherapy in three different types of NHL, diffuse large B-cell lymphoma (DL ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE